Диссертация (1140386), страница 21
Текст из файла (страница 21)
The terminal ileum is affected inpatients with lymphocytic or collagenous colitis. // Am J Surg Pathol.2002;26(11):1484-92.] и от 4,7 до 14,7174.Sapp H, Ithamukkala S, Brien TP, et al. The terminal ileum is affected inpatients with lymphocytic or collagenous colitis. // Am J Surg Pathol.2002;26(11):1484-92.175.Scharl M., Vavricka S.R., Rogler G. Review: new anti-cytokines forIBD: what is in the pipeline? // Curr. Drug Targets.
2013. Т. 14. № 12. С.1405–20.176.Seven G. et al. Use of anti tumor necrosis factor-alpha monoclonalantibody for ulcerative jejunoileitis. // World J. Gastroenterol. 2012. Т. 18. №36. С. 5135–7.177.Sharkey K.A., Kroese A.B. Consequences of intestinal inflammation onthe enteric nervous system: neuronal activation induced by inflammatorymediators. // Anat.
Rec. 2001. Т. 262. № 1. С. 79–90.178.Shen J. et al. Intestinal protein expression profile identifies inflammatorybowel disease and predicts relapse. // Int. J. Clin. Exp. Pathol. 2013. Т. 6. № 5.С. 917–25.129179.Shim J.O., Seo J.K. Very early-onset inflammatory bowel disease (IBD)in infancy is a different disease entity from adult-onset IBD; one form ofinterleukin-10 receptor mutations. // J. Hum. Genet. 2014. Т. 59.
№ 6. С. 337–41.180.Shioya M. et al. Epithelial overexpression of interleukin-32alpha ininflammatory bowel disease. // Clin. Exp. Immunol. 2007. Т. 149. № 3. С.480–6.181.Sigalet D.L. et al. Enteric neural pathways mediate the antiinflammatory actions of glucagon-like peptide 2. // Am.
J. Physiol.Gastrointest. Liver Physiol. 2007. Т. 293. № 1. С. G211–21.182.Sjojund K, Sanden G, Hakanson R, Sundler F. Endocrine cells in humanintestine: an immunocytochemical study. Gastroenterology 1983; 85;1120±1130183.Sjojund K, Sanden G, Hakanson R, Sundler F. Endocrine cells in humanintestine: an immunocytochemical study. Gastroenterology 1983; 85;1120±1130.184.Smyth C.M. et al. Activated eosinophils in association with entericnerves in inflammatory bowel disease. // PLoS One. 2013.
Т. 8. № 5. С.e64216.185.Sobczak M. et al. Nociceptin / orphanin FQ (NOP) receptors as novelpotential target in the treatment of gastrointestinal diseases. // Curr. DrugTargets. 2013. Т. 14. № 10. С. 1203–9.186.Sostegni R., Daperno M., Scalglione N. (2003) Review article: Crohn'sdisease: monitoring disease activity. Aliment Pharmacol.
Ther. 7; 2: 11>17187.Sunil Samuel, David H. Bruining, Edvard V. Loftus JR, et al. Validationof the Ulcerative Colitis Colonoscopic Index of Severity and Its CorrelationWith Disease Activity Measures188.Sura R., Colombel J.-F., Kruiningen H.J. Van.
Lymphatics, tertiarylymphoid organs and the granulomas of Crohn’s disease: animmunohistochemical study. // Aliment. Pharmacol. Ther. 2011. Т. 33. № 8. С.930–9.189.Surawicz CM, Belic L. Rectal biopsy helps to distinguish acute selflimited colitis form idiopathic inflammatory bowel disease. Gastroenterology,1984; 86: 104-113.190.Surawicz CM, Rubin CE. Epithelioid granuloma and related histologicfeatures which may differentiate Crohn’s disease from ulcerative colitis inrectal biopsies: Inflammatory bowel diseases. Edited by Rachmilewitz D.
TheHague, Martinus Nijhoff publishers, 1982, pp 19-26.130191.Talero E., Garcia-Maurino S., Motilva V. Melatonin, autophagy andintestinal bowel disease. // Curr. Pharm. Des. 2014. Т. 20. № 30. С. 4816–27.192.Taupenot L., Harper K.L., O’Connor D.T. The ChromograninSecretogranin Family. // N Engl J Med. 2003;348(12):1134-49.193.Tavano F. et al.
Neuroimmune interactions in patients with inflammatorybowel diseases: disease activity and clinical behavior based on Substance Pserum levels. // J. Crohns. Colitis. 2012. Т. 6. № 5. С. 563–70.194.ten Bokum AM, Hofland LJ, van Hagen PM., Somatostatin andsomatostatin receptors in the immune system: a review. Eur Cytokine Netw.2000 Jun;11(2):161-76.195.Troncone E. et al. Th17 cytokines in inflammatory bowel diseases:discerning the good from the bad. // Int. Rev. Immunol.
Т. 32. № 5-6. С. 526–33.196.Tsutsumi A, Takano H, Ichikawa K, et al.,1997. Expression ofsomatostatin receptor subtype 2 mRNA in human lymphoid cells. CellImmunol. 181: 44.197.Turner K. et al. Significance of the epithelioid granuloma in biopsies ofCrohn’s colitis. // Inflamm. Bowel Dis. 2014.
Т. 20. № 12. С. 2271–5.198.Valdez-Morales E. et al. Release of endogenous opioids during a chronicIBD model suppresses the excitability of colonic DRG neurons. //Neurogastroenterol. Motil. 2013. Т. 25. № 1. С. 39–46.e4.199.van Hagen P M, Krenning E P, Kwekkeboom D J, Reubi J C, et al.,1994.Somatostatin and the immune and haematopoietic system; a review. Eur.
J.Clin. Invest. 24: 91.200.Van Patter WN, Bargen JA, Dockerty MB, Feldman WH, Mayo CW,Waugh JM. Regional enteritis. Gastroenterology, 1954; 26: 347-375.201.Vanuytsel T. et al. Psychological stress and corticotropin-releasinghormone increase intestinal permeability in humans by a mast cell-dependentmechanism. // Gut. 2014. Т. 63. № 8. С. 1293–9.202.Vereecke L. et al. A20 controls intestinal homeostasis through cellspecific activities.
// Nat. Commun. 2014. Т. 5. С. 5103.203.Vermeulen W. et al. Neuroanatomy of lower gastrointestinal paindisorders. // World J. Gastroenterol. 2014. Т. 20. № 4. С. 1005–20.204.Vivinus-Nébot M. et al. Functional bowel symptoms in quiescentinflammatory bowel diseases: role of epithelial barrier disruption and lowgrade inflammation. // Gut. 2014. Т. 63. № 5. С. 744–52.205.Vossenkämper A.
et al. A CD3-specific antibody reduces cytokineproduction and alters phosphoprotein profiles in intestinal tissues from patients131with inflammatory bowel disease. // Gastroenterology. 2014. Т. 147. № 1. С.172–83.206.Wakefield A.J., Montgomery S.M. Immunohistochemical analysis ofmeasles related antigen in IBD. // Gut. 2001.
Т. 48. № 1. С. 136–7.207.Wang G.-F. et al. Clinical characteristics of non-perianal fistulatingCrohn’s disease in China: a single-center experience of 184 cases. // Chin.Med. J. (Engl). 2012. Т. 125. № 14. С. 2405–10.208.Waser B, Tamma ML, Cescato R, et al., 2009 Highly efficient in vivoagonist-induced internalization of sst2 receptors in somatostatin target tissues.J Nucl Med 50:936–941209.Winter B.Y. De, Wijngaard R.M. van den, Jonge W.J.
de. Intestinal mastcells in gut inflammation and motility disturbances. // Biochim. Biophys. Acta.2012. Т. 1822. № 1. С. 66–73.210.World J Gastroenterol 2005; 11(20): 3118-3121211.Xiao L., et al. Somatostatin regulates tight junction proteins expressionin colitis mice. Int J Clin Exp Pathol 2014; 7(5): 2153-2162212.Yu C.G., Huang Q. Recent progress on the role of gut microbiota in thepathogenesis of inflammatory bowel disease.
// J. Dig. Dis. 2013. Т. 14. № 10.С. 513–7.213.Zatelli M.C., Torta M., Leon A. Chromogranin A as a marker ofneuroendocrine neuplasia: an Italian multicenter Study. // Endocr Relat Cancer.2007;14(2):473-82214.Zhang B. et al. [Expression of interleukin 18 in intestinal mucosa ofpatients with inflammatory bowel disease and its implications]. // Beijing DaXue Xue Bao. 2003.
Т. 35. № 2. С. 150–3.215.Zhang Y., Li Y., Inflammatory bowel disease: Pathogenesis. // World JGastroenterol. 2014; 20(1): 91-99216.Ziogas D.C. et al. Anti-melanin-concentrating hormone treatmentattenuates chronic experimental colitis and fibrosis. // Am. J. Physiol.Gastrointest.
Liver Physiol. 2013. Т. 304. № 10. С. G876–84.217.Zurawski J. et al. Ki-67 and p53 expression in ileal pouches. // Pol. J.Pathol. 2012. Т. 63. № 2. С. 126–30.132.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
